BIO
Overvalued by 47% based on the discounted cash flow analysis.
Market cap | $8.20 Billion |
---|---|
Enterprise Value | $7.79 Billion |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $-21.82 |
Beta | 0.8 |
Outstanding Shares | 24,100,000 |
Avg 30 Day Volume | 202,322 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -12.86 |
---|---|
PEG | 22.16 |
Price to Sales | 2.51 |
Price to Book Ratio | 0.76 |
Enterprise Value to Revenue | 2.92 |
Enterprise Value to EBIT | 23.07 |
Enterprise Value to Net Income | -13 |
Total Debt to Enterprise | 0.15 |
Debt to Equity | 0.14 |
No data
No data